ENDECE Neural to Present Findings at 2013 Biotech Showcase on NDC-1308 which Induces Remyelination of Demyelinated Axons
MEQUON, Wis., Dec. 10, 2012 /CNW/ - ENDECE Neural, LLC (www.endeceneural.com) announced today that the company will be presenting at the 2013 Biotech Showcase in San Francisco, California, January 8th.
The ENDECE Neural presentation, to be given by Dr. James Yarger, CEO, will discuss the company's novel therapeutic for directly inducing remyelination of demyelinated axons to treat neurological diseases such as Multiple Sclerosis (MS).
Currently there are no drugs commercially available for remyelination in MS, or any other disease associated with demyelination. ENDECE Neural may have one of the first compounds with the ability to directly induce remyelination.
"This novel therapeutic could be used either alone or in combination with current immunosuppressant/anti-inflammation therapies," says Dr. Yarger. "We are looking to partner with or license this exciting opportunity to potentially restore function, mobility and independence to those fighting MS."
About ENDECE Neural, LLC (an ENDECE Company)
ENDECE Neural is the wholly owned subsidiary of ENDECE, LLC. ENDECE Neural was founded in 2011 to focus on the development of what could be the first drug capable of inducing remyelination of damaged nerve axons, and potentially restoring muscle control, mobility and independence to the lives of Multiple Sclerosis patients. ENDECE Neural maintains an exclusive license for the IP from its parent company.
About Biotech Showcase (Innovation – Opportunity – Collaboration)
Now in its fifth year, Biotech Showcase (www.ebdgroup.com/bts) features corporate presentations by 195 innovative life science companies to public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry.
SOURCE: ENDECE Neural, LLCFor further information:
Jean Yarger, Chief Administrative Officer, ENDECE, LLC, +1-262-240-9690, Jean.email@example.com